Advanced Cell Technology (ACTC.OB or ACT) filed an Investigational New Drug (IND) application on 11/18/09 to conduct a PI/II trial using hESCs to treat a genetic eye disease. Read more…
Stem cell technologies are anticipated to provide the stimulus for cellular repair or regeneration. This can be achieved in different ways: by administering stem cells, or specific cells that are derived from stem cells in the laboratory or by administering drugs that coax stem cells that are already present in tissues to more efficiently repair the involved tissue.
Referencing our multiple financing structure posts re PIPEs and RDOs; a new survey identifies key drivers of private investment in public equities in “next” 12-18 months. The survey conducted in Q3/09, canvassed the opinions of experienced PIPE investors, private equity practitioners, venture capital investors, hedge fund managers and mutual fund investors.
Referencing our previous post, “The Need to Continue Funding for Cancer Compounds” about cancer drugs in development … President Barack Obama recently announced a plan to spend $5 B on medical and scientific research, medical supplies and upgrading laboratory capacity. The funds, to come from the $787 B economic stimulus package will “pay” for cutting-edge medical research in every state across America. Could we assume that the word ”pay” might equate to “investment”? Read more…
A recent MassBio report found the number of biotechs in the state increased to about 400 over the past 7 years and the number of employees increased from 30,000 to 40,000. But the report also warned that 1/2 of the state’s publicly traded biotechs are in danger of running out of cash before the end of the year.
The effects of this current economic climate has put increased Read more…
Pharmaceutical researchers are now working on 861 medicines for cancer. Many are are in development involving innovative research on using existing medicines in new ways with many clinical trials proceeding. The medicines in development—all in either clinical trials or under FDA review including: 122 for lung cancer, the leading cause of cancer death in the United States:
All agree that small-cap healthcare companies – if they are to survive – need access to capital. Referencing previous financing and structures posts: these events could be a sign of a broader market recovery as I-Banks ramp-up their capacity and capability in restructuring, advisory and underwriting. Large and small investment banks such as: Wells Fargo, Bank of America Merrill Lynch, Centerview Partners, Jefferies & Company, Morgan Joseph, Thomas Weisel Partners and Leerink Swann have hired bankers amid expectations of financing activity.
I keep reiterating, research coverage is still the starting point of an investment decision.
Another financing vehicle is being utilized by small-cap healthcare companies: the Standby Equity Distribution Agreement (SEDA). This relatively new “mechanism” is another … alternative to Read more…
In today’s capital markets; this old but new (usage) capital-raising rage has many small-cap healthcare companies filling their coffers after finding that
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.